🇺🇸 FDA

Company profile · Sponsor

DiaMedica

DiaMedica Therapeutics

DMAC · NYSE pharma MINNEAPOLIS, MN, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

DiaMedica (DMAC) is a pharma company. headquartered in MINNEAPOLIS, MN, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker DMAC
Exchange NYSE
Company type pharma
Headquarters MINNEAPOLIS, MN, USA
SEC CIK 0001401040

Pipeline (8)

Search pipeline →

  1. Recombinant human tissue kallikrein

    DiaMedica

    Acute Stroke

    phase 3 small molecule active

    1 trial

  2. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  3. DM199

    DiaMedica

    Diabetes Type 2

    phase 2 small molecule completed

    1 trial

  4. DM199

    DiaMedica

    Kidney Diseases

    phase 2 small molecule completed

    1 trial

  5. Recombinant human tissue kallikrein

    DiaMedica

    Acute Ischemic Stroke

    phase 2 small molecule completed

    1 trial

  6. DM199

    DiaMedica

    Chronic Kidney Disease

    phase 1 small molecule completed

    1 trial

  7. Recombinant human tissue kallikrein

    DiaMedica

    Stroke

    phase 1 small molecule completed

    1 trial

  8. DM199

    DiaMedica

    Pre-Eclampsia

    mab terminated

    1 trial

Patents (8)

Search patents →

  1. US 12329805

    Dosage forms of tissue kallikrein 1

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11857608

    Dosage forms of tissue kallikrein 1

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11725043

    Ulinastatin polypeptides

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9839678

    Human tissue kallikrein 1 glycosylation isoforms

    Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9616015

    Formulations of human tissue kallikrein-1 for parenteral delivery and related methods

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9364521

    Human tissue kallikrein 1 glycosylation isoforms

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8673964

    Use of drug combinations for treating insulin resistance

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8501695

    Tissue kallikrein for the treatment of diseases associated with amyloid protein

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is DiaMedica?

DiaMedica (DMAC) is a pharma company. headquartered in MINNEAPOLIS, MN, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does DiaMedica sponsor?

We track 8 ClinicalTrials.gov-linked programs for DiaMedica, including Recombinant human tissue kallikrein and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does DiaMedica company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.